Teams must work together with technology solutions and optimize integration to unlock their full potential. Clinical trials ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, discusses the need for change in the clinical research ...

Clinical trials are notoriously expensive, with operational expenses ranging from $50 million to over $115 million. 1 The ...

Ron Lanton, Partner, Lanton Law, discusses how stakeholders must navigate funding future clinical research amid NIH budget ...

In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, talks innovation in clinical technology and how the FDA can continue to promote its adoption.

A tool-based approach can significantly aid in the harmonization of regulatory requirements, mitigate inadvertent risks, and ...

In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, talks FDA’s latest ...

Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...

Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...